

# ALZHEIMER'S THERAPY

## Referral Form



**DELIVERIT**<sup>TM</sup>  
Infusion & Specialty

Phone +1.832.939.8137

Fax: +1.832.939.8128

### Patient Demographic Information

(Or Attach Face Sheet from Patient Chart)

Patient Name		DOB		Gender	Male <input type="checkbox"/> Female <input type="checkbox"/>	Weight	_____lbs <input type="checkbox"/> kg <input type="checkbox"/>		
SSN		Phone		Allergies					
Address				City		State		Zip Code	
Patient Status	<input type="checkbox"/> New to Therapy <input type="checkbox"/> Continuing Therapy			Next Treatment Date					

### Patient Insurance Information

(Or Attach Copies of Patient's Insurance Card)

Primary Insurance		Name of the Insured			Relationship		
Member ID#		Group #			Insurance Phone #		
Secondary Rx Carrier				Rx ID #		Rx Group #	

### Medical Information

- Diagnosis:** ☐ Alzheimer's Disease with Early Onset (ICD-10 code: G30.0)  
☐ Alzheimer's Disease with Late Onset (ICD-10 code: G30.1)  
☐ Other Alzheimer's Disease (ICD-10 code: G30.8)  
☐ Alzheimer's Disease, unspecified (ICD-10 code: G30.9)  
☐ Mild cognitive impairment, so stated (ICD-10 code: G31.84)  
**-AND-**  
☐ Encounter for clinical registry program (ICD-10 code: Z00.6), **Medicare required**

### Therapy Orders

**Leqembi:** ☐ 10mg/kg IV every 2 weeks  
(lecanemab)

- MRIs should be performed at baseline & prior to the 5th, 7th, and 14th infusion
- HOLD infusion if MRI is not performed at indicated interval

**Kisunla:** ☐ 700mg IV every 4 week for 3 doses, then 1400mg IV every 4weeks thereafter  
(donanemab)

☐ Maintenance: 1400mg IV every 4 weeks

- MRIs should be performed at baseline & prior to the 2nd, 3rd, 4th, and 7th infusion
- HOLD infusion if MRI is not performed at indicated interval

Refill for: ☐ 6 months ☐ 1 year ☐ Other: \_\_\_\_\_

**Additional orders:** \_\_\_\_\_

**Lab orders:** \_\_\_\_\_ **Lab frequency:** \_\_\_\_\_

# ALZHEIMER'S THERAPY

## Referral Form



**DELIVERIT™**  
Infusion & Specialty

Phone +1.832.939.8137

Fax: +1.832.939.8128

### Required Documentation For Referral Processing & Insurance Approval

- ☐ Include signed and completed order (MD/prescriber to complete page 1)
- ☐ Include patient demographic information and insurance information
- ☐ Include patient's medication list
- ☐ Supporting clinical notes (H&P) to support primary diagnosis
- ☐ Other medical necessity: \_\_\_\_\_

### Required

#### ☐ Patient enrolled in the CMS National Patient Registry (Medicare & Medicare Advantage required)

Issue number: \_\_\_\_\_ Date of registry enrollment: \_\_\_\_\_

- ☐ Provide copy of CMS national patient registry confirmation

#### ☐ Confirmed presence of amyloid pathology

Attach results: Amyloid PET scan OR +CSF (cerebrospinal fluid)

#### ☐ MRI of the brain (within 1 year) - attach results

#### ☐ Cognitive assessment scores (list all available, attach results):

☐ MMSE: Score \_\_\_\_\_ Date of assessment \_\_\_\_\_

☐ MoCA: Score \_\_\_\_\_ Date of assessment \_\_\_\_\_

☐ CDR: Score \_\_\_\_\_ Memory box: Score \_\_\_\_\_ Date of assessment \_\_\_\_\_

☐ Other: \_\_\_\_\_ Score \_\_\_\_\_ Date of assessment \_\_\_\_\_

#### ☐ Functional assessment score: \_\_\_\_\_ (attach results)

Assessment Name: ☐ FAQ ☐ FAST ☐ Other: \_\_\_\_\_ Assessment date: \_\_\_\_\_

#### ☐ Include labs and/or test results for the following:

- ☐ Genotype testing for ApoE4

-OR-

- ☐ ApoE4 genetic testing has NOT been completed. Provider has counselled the patient on how testing for ApoE4 status informs the risk of developing ARIA and the patient has shared decision-making to initiate Leqembi

#### ☐ Does the patient have objective impairment in episodic memory as evidenced by a memory test (i.e., Free and Cued, Wechsler, etc.)? (BCBS required) ☐ Yes ☐ No

#### ☐ Is the patient on therapeutic anticoagulation/antiplatelet therapy? ☐ Yes ☐ No

If yes, please note therapy and dose: If yes, please note therapy and dose: \_\_\_\_\_

### Prescriber Insurance Information

Prescriber Name		NPI#		Office #		Fax #	
Address		City		State		Zip Code	
<input type="checkbox"/> I Authorize DeliverIt specialty pharmacy to initiate Prior Authorizations on my behalf.				Date			
<input type="checkbox"/> DAW (Dispense as written).				Prescriber's Signature  X _____			
<small>Prescriber certifies that this referral form contains an original signature and is signed by the treating prescriber. No stamped signatures will be accepted. Where required by law, send electronic prescription or on official state prescription blank. In the event requested agent is not available through DeliverIt Group, this prescription shall be forwarded to an eligible pharmacy.</small>							

Please fax all information to (832)939-8128 or call (877)993-3548 for assistance  
Our local number 832-939-8137